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Some adults fail to adapt to chronic stress, developing symptoms of depression and anxiety. In this issue of
Neuron, Uchida and colleagues link maladaptive stress responses to GDNF through a comprehensive inves-
tigation of the neurotrophic factor’s regulation. Further, this study is an excellent example for investigators
interested in neuroepigenetics research.Major depressive disorder affects nearly
10% of the adult population in the US
and is the country’s leading cause of
disability. Many do not respond to treat-
ment and those that do experience
a high rate of recurrence. A great deal
of attention is focused on developing
effective treatments for this debilitating
disorder. However, an additionally impor-
tant goal is prevention (Holtzheimer and
Nemeroff, 2006; Avenevoli and Merikan-
gas, 2006). This seemingly simple goal
requires unraveling the complexities that
underlie the development of depression
and the associated risk factors. Early-life
stress can predispose individuals tomajor
depressive disorder in adulthood through
a variety of mechanisms, including lasting
epigenetic modifications (Meaney and
Szyf, 2005). As the term suggests, ‘‘epi-
genetics’’ refers to persisting changes
made above the genome. But in addition
to early-life stress, chronic stress in adult-
hood also appears to precipitate depres-
sion in some individuals. As we are all
too aware, chronic stress is a common
experience for adults and has a number
of deleterious effects. These range from
weakening the strength of our immune
system to damaging our mental health
(McEwen, 2000). An impressive number
of mechanisms have been identified in
relation to the development of depression,
including epigenetic regulation of the
growth factor brain-derived neurotrophic
factor (BDNF) (Krishnan and Nestler,
2008), and the field is beginning to under-
stand the contribution of stress through
interactions between corticotrophin re-
leasing factor (CRF) and serotonin recep-
tors (Magalhaes et al., 2010). But the
glaring question remains: why does stress188 Neuron 69, January 27, 2011 ª2011 Elseprecipitate depression in some adults,
while others are seemingly protected?
In this issue of Neuron, Uchida and
colleagues explored the specific contri-
bution of growth factors to stress-induced
susceptibility to depression (Uchida et al.,
2011). As a model of differential stress
response, the authors used the clever
approach of comparing two strains of
mice known to have different baseline
levels of anxiety-like behaviors. Relative
to C57BL/6J (B6) mice, BALB/cJ (BALB)
mice display high measures of anxiety
when tested for things like exploration of
the center of an open field and time spent
in the arms of an elevated plus maze that
lacks walls. Uchida et al. (2011) subjected
‘‘low anxiety’’ B6 and ‘‘high anxiety’’
BALBmice to 6weeks of mild, daily stress
and employed tests designed to assess
behaviors associated with symptoms of
depression: anxiety (novelty suppressed
feeding), despair (forced swim test), anhe-
donia (sucrose preference test), and
avoidance of social situations (social inter-
action test). Results of the behavior tests
indicated that B6 mice adapted well to
the chronic stress. BALB mice, on the
other hand, experienced an exacerbation
of their anxiety-like behaviors and devel-
oped depression-like behaviors.
To identify potential growth factors
contributing to this differential stress
response, the authors next compared
transcript levels of nine different neurotro-
phic factors (e.g., BDNF, GDNF, IGF, etc.)
in five different brain regions (e.g., hippo-
campus, prefrontal cortex, etc.) of the
BALB mice with and without chronic
stress. GDNF expression in the nucleus
accumbens (NAc) emerged as a factor
of particular interest. Following chronicvier Inc.stress, GDNF’s transcript and protein
levels were decreased in BALB mice but
increased in B6. Importantly, the BALB
behavioral deficits that correlated with
GDNF levels were corrected by GDNF
overexpression in the NAc. Based on
this convincing data for GDNF’s important
role in developing an adaptive stress
response, the authors then embarked on
a heroic endeavor directed at identifying
the mechanism(s) of GDNFmisregulation.
It almost seems criminal to summarize
some of their months-long experiments
with a single sentence. Nevertheless, I
will do just that—with the goal of clearly
conveying the group’s exciting findings.
Resequence analysis of the GDNF pro-
moter revealed no differences between
strains, so the authors focused their
efforts on epigenetic-induced differences
in GDNF regulation (Figure 1). Epigenetic
mechanisms consist of a set of posttrans-
lational modifications (PTMs) of DNA and
histone proteins that produce lasting
alterations in chromatin structure and
gene expression. Highly basic histone
proteins are the major component of
chromatin and in its native state, tran-
scription is repressed through tight
binding of histones to DNA. This binding
prevents the necessary RNA polymerase
II enzyme interaction. Therefore, chroma-
tin’s tightly bound structure must be
disrupted in order for transcription to
occur. This can be achieved through
acetylation and phosphorylation of his-
tone tails, as these PTMs are associated
with transcriptional activation. The cova-
lent modification of DNA, on the other
hand, induces long-term suppression of
gene expression through direct interfer-
ence with transcription factor binding
Figure 1. Epigenetic Regulation of GDNF in the ‘‘Low Anxiety’’ B6 and ‘‘High Anxiety’’ BALB Mouse Strains following Chronic Stress
Chronic stress induces DNAmethylation of GDNF’s promoter and recruitment ofMeCP2 in the NAc of both low-anxiety B6mice and high-anxiety BALBmice. The
differential transcription rates of GDNF may be accounted for by MeCP2’s recruiting partner. In BALB mice, MeCP2 recruits HDAC2, which presumably deace-
tylates GDNF’s promoter, leading to the gene’s transcriptional repression. However, in B6 mice, MeCP2 recruits CREB, creating a complex demonstrated to
support transcriptional activation. Together with as-yet-unknown mechanisms, epigenetic repression of GDNF leads to maladaptive stress responses in the
BALB mice, including anxiety and depression-like behaviors.
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enzymes via the action of methyl-
CpG binding proteins (MBDs), such as
MeCP2. While an oversimplification of
the process, cytosines located next to
guanines (CpGs) are preferentially meth-
ylated. This is particularly true in CpG-
rich regions known as CpG islands.
The authors began by measuring asso-
ciation between GDNF’s promoter region
and the transcriptionally active mark of
acetylation on histone H3 (H3Ac).
Following stress, H3Ac-GDNF associa-
tion was decreased in BALB mice but
increased in B6 mice. This was consistent
with the GDNF transcript levels measured
in the previous experiment. Acetyl groups
are actively removed from histones by
histone deacetylase enzymes (HDACs).
Covering all of the class I, II, and IV
HDACs, the authors next examined
HDACs 1–11 in the NAc and found that
only HDAC2 was altered by stress. The
HDAC2 increase was associated with
GDNF’s promoter and specific to stressed
BALB mice, further developing a modelwhere GDNF is actively suppressed with
stress by removal of H3Ac from GDNF’s
promoter. Histone acetylation can be
pharmacologically elevated by treatment
with various HDAC inhibitors (HDACi).
The HDACi SAHA targets class I HDACs,
including HDAC2 (Kilgore et al., 2010).
The authors demonstrated that both
systemic treatment with SAHA and local
viral-mediated knockdown of HDAC2 in
the NAc normalized GDNF levels, as
well as the anxiety and depression-like
behaviors in stressed BALB mice. Con-
versely, overexpression of HDAC2 further
exacerbated the BALBs’ maladaptive
behavioral and transcriptional responses
to stress.
Histone acetylation can work with DNA
methylation to regulate gene transcription
and behavior (Miller et al., 2008). There-
fore, the authors used bisulfite mapping
to detail the specific sites of cytosine
methylation within GDNF’s promoter and
just downstream of the transcription start
site. One promoter CpG site (CpG 2) was
hypermethylated in the NAc of bothNeuron 69strains of mice with stress, while another
was specifically hypermethylated in
stressed BALB mice (CpG 3). Stress also
increased levels of DNMT 1 and 3a, iso-
forms of the enzymes responsible for
methylating DNA. Continuous delivery of
a DNMT inhibitor into the NAc via an
osmotic pump reversed the GDNF hyper-
methylation, reduction in GDNF mRNA
and malapdaptive behavioral stress
responses in the BALB mice.
MBDs, such as MeCP2, bind to methyl-
ated DNA and repress transcription.
Unexpectedly, MeCP2 binding to the
GDNF promoter was elevated in both
strains of mice following stress. The
authors have now observed two putative
negative regulators of transcription in
both strains with stress. To understand
this apparent paradox in epigenetic
tagging, the authors next explored
the specific proteins that complexed
with MeCP2 on GDNF’s promoter. Asso-
ciation of a MeCP2-HDAC2 complex
with GDNF’s promoter was specifically
increased in stressed BALB mice. As, January 27, 2011 ª2011 Elsevier Inc. 189
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epigenetic changes is consistent with
the transcriptional repression of GDNF
observed in the stressed BALB mice. On
the other hand, in stressed B6 mice,
MeCP2-CREB complexed with GDNF’s
promoter. The authors’ clever examina-
tion of a MeCP2-CREB complex arose
from the finding that MeCP2-CREB
binding to methylated DNA can have the
unexpected effect of activating transcrip-
tion (Chahrour et al., 2008). In support of
this possibility, there is a predicted CRE
site adjacent to the CpG that was hyper-
methylated in both strains (CpG 2). There-
fore, this complex is consistent with
the transcriptional activation of GDNF
measured in stressed B6 mice (Figure 1).
As with any compelling study, the find-
ings of Uchida and colleagues (2011) raise
important questions. The authors clearly
demonstrate the beneficial behavioral
effects of GDNF upregulation in the NAc
of stressed BALB mice. Further, the
authors recognize that GDNF-HDAC2
interactions are unlikely to be the only
factor involved in the BALB’s maladaptive
response to stress. Along these lines, it
would be very instructive to see if the
beneficial effects of SAHA or viral-medi-
ated knockdown of HDAC2 are negated
by concomitant knockdown of GDNF.
If not, a microarray or deep-sequencing
approach could be used to identify addi-
tional transcriptional targets regulated by
SAHA. In light of the developing case for
HDACi treatment of depression (Coving-
ton et al., 2009; Grayson et al., 2010),
this question of SAHA’s targets under
stressful conditions is of particular
interest. Along these same lines, the
authors examined the effect of SAHA in
stressed BALB mice and found that it
normalized their social inhibition, anhe-
donia, and anxiety. It would be interesting
to know what effect SAHA would have
under the same conditions of stress in
B6 mice. Drawing a parallel between
the adaptive B6 mice and the human190 Neuron 69, January 27, 2011 ª2011 Elsecondition introduces a question: what if
an individual that is properly coping with
daily stress were mistakenly prescribed
an HDACi? Could the drug have the
potential to shift behavior to the point
of removing adaptive inhibitions (e.g., in
social situations)?
The work by Uchida and colleagues
(2011) also raises a cautionary point with
regards to methodology that is relevant
to any researcher interested in investi-
gating DNA methylation. While laborious,
the authors used the most detailed
method of DNA methylation analysis,
sodium bisulfite mapping. Unfortunately,
a recent discovery has revealed a chal-
lenge that all epigeneticists, but particu-
larly those studying the brain, must
grapple with. Bisulfite modification, the
critical step in sodium bisulfite mapping,
protects both 5-methylcytosine (5mC)
and a relatively new player, 5-hydroxy-
methylcytosine (5hmC). This means that
bisulfite mapping cannot distinguish
between 5mC and the ‘‘sixth base,’’
5hmC. This is a particularly serious com-
plication for neuroscientists to consider
going forward because the highest
levels of 5hmC are found in the brain
and its exact function is still unclear (Glo-
bisch et al., 2010). Fortunately, new
methods of detection have been pub-
lished in the past few months that will
slowly begin to be incorporated into
the already complicated toolbox for epi-
genetic detection.
The findings of Uchida and colleagues
(2011) further suggest the intriguing
possibility that GDNF serum levels may
be predictive of an individual’s coping
ability. Interestingly, GDNF serum levels
are reported to be lower in patients with
major depression and bipolar disorder
(Takebayashi et al., 2006), and a positive
response to electroconvulsive therapy in
patients with pharmacologic-resistant
depression has been associated with
increased GDNF serum levels (Zhang
et al., 2009). Perhaps individuals with avier Inc.family history of depressionmay someday
benefit from a test of their stress-induced
GDNF response and subsequent pharma-
cologic intervention.REFERENCES
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